Creating High-quality RNA-sequencing Reference Data from ATCC's Verified Cell Lines

Ajeet P. Singh, PhD; Amy L. Reese, MS; Rula Khairi, MS; Steve King, MS; Ana Fernandes, BS; John Bagnoli, BS; Briana Benton, BS; Jonathan L. Jacobs PhD ATCC, Manassas, VA 20110

Introduction

Access to reliable RNA-seq reference data from verified ATCC[®] cell lines is pivotal for progressing biomedical research. Nevertheless, there is a notable absence of datasets in the public domain that precisely mirrors the RNA characteristics linked with these cell lines. This kind of resource is fundamental for establishing a baseline control when utilizing these cell lines across diverse studies. Employing meticulous RNA sequencing techniques and rigorous quality checks, ATCC[®] has partnered with QIAGEN[®] Digital Insights and created the ATCC[®] Cell Line Land tool—an online platform featuring extensive transcriptomic and genomic data from the source material, serving as the benchmark reference standard.

Our ongoing sequencing endeavors to provide a thorough inventory of RNA transcripts shed light on the fundamental gene expression profiles within ATCC[®] cell lines. Through comparative analyses, distinct RNA expression patterns have emerged, delineating molecular discrepancies among various cell lines. Notably, our examination has delineated relative basal gene expression levels between genetically modified cells versus native ones and between healthy primary and cancerous cells. This information holds significance in the selection of cell lines for study and subsequent analysis. Integrative analyses of ATCC[®] Cell Line Land RNA-seq data with existing genomic and proteomic datasets in the public domain facilitates the validation of results across different data types, enabling comprehensive multi-omics analyses and mitigating ambiguity while enhancing clarity in data interpretation. Furthermore, comparative analysis of ATCC derived cell line RNA-seq data could aid in predicting cellular responses to treatment, facilitating drug screening, and anticipating potential outcomes. We advocate for collaborative endeavors to continually update and refine these high-quality reference databases, ensuring their pertinence and utility in the dynamic landscape of research.

Materials & Methods



ISO 9001 standards.

Molecular characterization of ATCC's cell lines



Figure 2: The ATCC[®] Cell Line Land (ACLL) project intends to map all human and mouse cell lines to promote reproducibility and scientific rigor in biomedical research. This perspective highlights the collaboration between QIAGEN® DIGITAL INSIGHTS and ATCC®. (A) ATCC cell lines characterized for molecular qualities derived from various tissue types and disease states. (B) Relative basal abundance of the tumor suppressor gene p53 in several cell lines. Green boxes indicate cell lines with negative expression, whereas red boxes indicate cell lines with high p53 mRNA levels. The X-axis in panel A indicates the number of RNA sequencing data sets produced from biological replicates of the respective cell lines.

> ATCC 10801 University Boulevard, Manassas, Virginia 20110-2209

QIAGEN is a registered trademark of the QIAGEN Group.

Baseline expression in models of kidney cancer



Figure 3: Molecular hallmarks in renal cancer subtypes. (A) Diagram displaying renal cell carcinoma subtypes. (B) Diagram illustrating the assembly of SWI/SNF complex subunits. (C) Heatmap depicting the differential expression of SWI/SNF subunits (x-axis) in the indicated renal carcinoma cell lines (y-axis). (D) Heatmap displaying the expression pattern of key genes (x-axis) in renal carcinoma subtypes (y-axis). (C, D) Red indicates induction while blue indicates reduction. (E) Box plots showing the relative mRNA levels of indicated genes in renal carcinoma subtypes. The data suggest both positive and negative correlations among expressed genes, indicating the intrinsic activity of molecules in renal cell cancer. (F) Venn diagram illustrating the number of genes shared and/or uniquely expressed in renal cancer cells versus normal control cells. HRCEPIC: Human Renal Cortical Epithelial Cell. The presented data shows multiple biological replicates of the respective cell line models

Phone: 800.638.6597 **Email:** sales@atcc.org Web: www.atcc.org © 2024 American Type Culture Collection. The ATCC trademarks indicated otherwise.

Tumor paired normal cell line comparison

Identifying pharmacological targets in polycystic kidney disease



Canonical pathways in kidney cell line

	Path	way H	leati	map	of	Con			
П	HALLMARK_ANGIOGENES	SI							
HALLMA	RK ESTROGEN RESPONSE E	A							
	HALLMARK_GLYCOLYS	5K							
> HALLMAF	RK_INTERFERON_ALPHA_RESP	0							
h wa	HALLMARK_MITOTIC_SPINE	DL							
Pat	HALLMARK_MYC_TARGETS	_\							
	HALLMARK_P53_PATHW	/A							
HALLMARK_REA	CTIVE_OXYGEN_SPECIES_PAT	н							
HALL	MARK_TNFA_SIGNALING_VIA_N	١F							
	HALLMARK_UV_RESPONSE	-6							
		L L	ЪГ	5					
		C.G	0.0	C.GI					
		ЗЕРІ	Б	EPI					
		HRO	SHR	HRC					
		Cvs	912v	37vs					
		HRE	MT	M					
		lney.	hey	hey					
		kic	kic	kic					
		Imar	ımar	ımar					
		H	린	린					
		TCC	TCC	TCC					
		∢	۷	∢					
Case.DiseaseCat	regory	С	omp	ariso	on				
C									
G									
Top Applysic B	adv Moloculor								
TOP Analysis-Ke	ady molecules								
✓ Expr Log	Ratio 🕇								
\vee Expr Log	Ratio 🕇								
✓ Expr Log Mo	Ratio 🕇						,	Valu	e
V Expr Log	Ratio 🕇							Valu	ie
✓ Expr Log Mol ZIC	Ratio 🕇 lecules 3						+	Valu 22.9	ie)19
V Expr Log Mol ZIC	Ratio + lecules 3 0_2636A232						† †	Valu 22.9 21.3	ie 919 947
V Expr Log Mol ZIC: CTL LA1	Ratio + lecules 3 0_2636A232 6C_390E65						+ + +	Valu 22.9 21.3 20.9	ie 919 947 925
V Expr Log Mol ZIC: CTC LA1 RP1	Ratio + lecules 3 0_2636A232 6C_390E65 1 316M112						+ + + +	Valu 22.9 21.3 20.9 20.3	ie)19)47)25)49
V Expr Log Mol ZIC: CTC LA1 RP1 VC4	Ratio + lecules 3 0_2636A232 6C_390E65 1_316M112						+ + + + +	Valu 22.9 21.3 20.9 20.3	ie)19)47)25)49)47
V Expr Log Mol ZIC: CTE LA1 RP1 VCA	Ratio + lecules 3 0_2636A232 6C_390E65 1_316M112 NN-AS1						+ + + + + +	Valu 22.9 21.3 20.9 20.3 20.0	ie 319 347 325 349 347
V Expr Log Mol ZIC: CTE LA1 RP1 VCA SLIT	Ratio + lecules 3 0_2636A232 6C_390E65 1_316M112 NN-AS1 TRK3						* * * * *	Valu 22.9 21.3 20.9 20.3 20.0 19.9	19 347 325 349 347 324
V Expr Log Mol ZIC: CTC LA1 RP1 VCA SLIT RP1	Ratio ↑ lecules 3 0_2636A232 6C_390E65 1_316M112 AN-AS1 TRK3 1_805J145						* * * * * *	Valu 22.9 21.3 20.9 20.3 20.0 19.9)19)47)25)49)47)24)77
V Expr Log Mol ZIC: CTE LA1 RP1 VC4 SLIT RP1 HO2	Ratio + lecules 3 0_2636A232 6C_390E65 1_316M112 NN-AS1 (RK3 1_805J145 XD13						* * * * * * *	Valu 22.9 20.9 20.3 20.0 19.9 19.1 18.9	ie 319 347 325 349 347 324 177 309
V Expr Log Mol ZIC: CTE LA1 RP1 VCA SLIT RP1 HO2 LOC	Ratio + lecules 3 0_2636A232 6C_390E65 1_316M112 NN-AS1 (RK3 1_805J145 XD13 (124902301						*****	Valu 22.9 21.3 20.9 20.3 20.0 19.9 19.1 18.9 18.8)19)47)25)49)47)24)24)77)24)77)09)89
V Expr Log Mol ZIC: LA1 RP1 VC4 SLIT RP1 HO2 LOC FEN	Ratio ↑ lecules 3 0_2636A232 6C_390E65 1_316M112 NN-AS1 (RK3 1_805J145 XD13 (124902301 IDRR						*****	Valu 22.9 21.3 20.9 20.3 20.0 19.9 19.1 18.9 18.8 18.5	19 347 325 349 347 324 177 309 389 334
V Expr Log Mol ZIC: CTE LA1 RP1 VCA SLIT RP1 HO2 LOC FEN	Ratio + lecules 3 0_2636A232 6C_390E65 1_316M112 AN-AS1 (RK3 1_805J145 XD13 (124902301 IDRR						*****	Valu 22.9 21.3 20.9 20.0 19.9 19.1 18.9 18.8 18.5	19 347 325 349 347 324 177 309 389 334
✓ Expr Log Mol ZIC: CTE LA1 RP1 VCA SLIT RP1 HO2 LOC FEN	Ratio ↑ lecules 3 0_2636A232 6C_390E65 1_316M112 NN-AS1 (RK3 1_805J145 XD13 (124902301 IDRR Ratio ↓						******	Valu 22.9 21.3 20.9 20.3 20.0 19.9 19.9 18.9 18.8 18.5)19)47)25)49)47)24 177)24 177)09)89 ;34
 ✓ Expr Log Mol ZIC: CTE LA1 RP1 VC4 SLIT RP1 HO2 LOC FEN ✓ Expr Log 	Ratio ↑ lecules 3 0_2636A232 6C_390E65 1_316M112 NN-AS1 (RK3 1_805J145 XD13 (124902301 IDRR Ratio ↓						* * * * * * * *	Valu 22.9 21.3 20.9 20.3 20.0 19.9 18.9 18.9 18.5))))))))))))))
 ✓ Expr Log Mol ZIC: CTE LA1 RP1 VCA SLIT RP1 HO: LOC FEN ✓ Expr Log Mol 	Ratio ↑ lecules 3 0_2636A232 6C_390E65 1_316M112 AN-AS1 (RK3 1_805J145 XD13 (124902301 IDRR Ratio ↓ lecules						******	Valu 22.9 21.3 20.9 20.3 20.0 19.9 19.1 18.9 18.8 18.5 Valu	ie 919 947 925 949 947 924 177 909 389 534
 ✓ Expr Log Mol ZIC: CTE LA1 RP1 VCA SLIT RP1 HO2 LOC FEN ✓ Expr Log Mol DD2 	Ratio ↑ lecules 3 0_2636A232 6C_390E65 1_316M112 NN-AS1 TRK3 1_805J145 XD13 124902301 IDRR Ratio ↓ lecules X3Y						+++++++++++++++++++++++++++++++++++++++	Valu 22.9 21.3 20.9 20.3 20.0 19.9 19.9 18.9 18.9 18.9 18.9 18.9 Valu -30.	e 919 347 925 349 947 924 177 909 389 534 e 472
 ✓ Expr Log Mol ZIC: CTD LA1 RP1 VC4 SLIT RP1 HO2 LOC FEN ✓ Expr Log Mol DD2 UTV 	Ratio ↑ lecules 3 0_2636A232 6C_390E65 1_316M112 NN-AS1 TRK3 1_805J145 XD13 124902301 IDRR Ratio ↓ lecules						* * * * * * * *	Valu 22.9 20.3 20.3 20.0 19.9 19.1 18.9 18.5 18.5 18.5 Valu -30.	ie 919 347 925 349 947 924 177 909 389 534 ie 472 289
 ✓ Expr Log Mol ZIC: CTE LA1 RP1 VCA SLIT RP1 RP1	Ratio ↑ lecules 3 0_2636A232 6C_390E65 1_316M112 N-AS1 TRK3 1_805J145 XD13 124902301 IDRR Ratio ↓ lecules X3Y						******	Valu 22.9 20.3 20.3 20.0 19.1 18.9 18.8 18.5 18.5 Valu -30. -28.	ie 919 947 925 949 947 924 177 909 989 534 ie 472 289 017
 ✓ Expr Log Mol ZIC: CTE LA1 RP1 VCA SLIT RP1 HO2 LOC FEN ✓ Expr Log Mol DD2 UTY TXL 	Ratio ↑ lecules 3 0_2636A232 6C_390E65 1_316M112 NN-AS1 TRK3 1_805J145 XD13 C124902301 IDRR Ratio ↓ lecules X3Y MGY						++++ ++++ +++++	Valu 22.9 21.3 20.9 20.3 20.0 19.9 19.9 18.9 18.9 18.9 18.9 18.9 18.9	e 347 325 349 347 324 177 309 389 534 e 472 289 017 407
 ✓ Expr Log Mol ZIC: CTE LA1 RP1 VCA SUIT RP1 HO2 LOC FEN ✓ Expr Log Mol DD2 UTY TXL RP5 	Ratio ↑ lecules 3 0_2636A232 6C_390E65 1_316M112 NN-AS1 rRK3 1_805J145 XD13 C124902301 IDRR Ratio ↓ lecules X3Y Y NGY 4Y1						* * * * * * * *	Valu 22.9 21.3 20.9 20.3 20.0 19.9 18.9 18.9 18.9 18.9 18.9 18.9 18.9	e 472 473 493 494 477 497 497 497
 ✓ Expr Log Mol ZIC: CTD LA1 RP1 VC4 SLIT RP1 HO2 LOC FEN ✓ Expr Log Mol DD2 UTY TXL RP5 PRK 	Ratio ↑ lecules 3 0_2636A232 6C_390E65 1_316M112 NN-AS1 TRK3 1_805J145 XD13 C124902301 IDRR Ratio ↓ lecules X3Y NGY 4Y1 Y						+++++	Valu 22.9 21.3 20.9 20.3 20.0 19.9 19.1 18.9 18.8 18.5 18.5 18.5 18.5 18.5 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20	ie 919 347 925 349 947 924 177 909 389 534 ie 472 289 017 497 364
 ✓ Expr Log Mol ZIC: CTE LA1 RP1 VCA SLIT RP1 SLIT RP1 SLIT SLIT<	Ratio ↑ lecules 3 0_2636A232 6C_390E65 1_316M112 AN-AS1 TRK3 1_805J145 XD13 C124902301 IDRR Ratio ↓ lecules X3Y VICENTY V						++++++	Valu 22.9 21.3 20.9 20.3 20.0 19.9 19.9 18.8 18.9 18.8 18.5 Valu -30. -28. -28. -28. -26. -25.	e 919 347 925 349 924 177 909 389 534 e 472 289 017 364 561
 ✓ Expr Log Mol ZIC: CTE LA1 RP1 VCA SLIT RP1 SLIT RP3 PR4 USF ACC 	Ratio 1 lecules lecules lecules lecules lecules lecules lecules lecules X3Y NGY Higher Structure						++++++	Valu 22.9 21.3 20.9 20.3 20.0 19.9 19.9 18.9 18.9 18.9 18.9 18.9 18.9	e 919 347 925 349 947 924 177 909 389 534 e 472 289 017 497 364 561 485
 ✓ Expr Log Mol ZIC: CTD LA1 RP1 VCA SUIT RP1 HO2 LOC FEN ✓ Expr Log Mol DD2 UTY TXL RPS PRK USF ACC 	Ratio ↑ lecules 3 0_2636A232 6C_390E65 1_316M112 NN-AS1 rRK3 1_805J145 XD13 2124902301 IDRR Ratio ↓ lecules X3Y Y <tr< th=""><th></th><th></th><th></th><th></th><th></th><th>* * * * * * * * * * * * * * *</th><th>Valu 22.9 21.3 20.9 20.3 20.0 19.9 19.1 18.9 18.9 18.9 18.5 18.5 18.5 18.5 18.5 18.5 18.5 18.5</th><th>e 919 947 925 949 947 924 177 909 989 934 177 909 989 934 177 909 989 934 177 909 989 934 177 909 989 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 935 147 147 147 147 147 147 147 147</th></tr<>						* * * * * * * * * * * * * * *	Valu 22.9 21.3 20.9 20.3 20.0 19.9 19.1 18.9 18.9 18.9 18.5 18.5 18.5 18.5 18.5 18.5 18.5 18.5	e 919 947 925 949 947 924 177 909 989 934 177 909 989 934 177 909 989 934 177 909 989 934 177 909 989 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 909 934 177 935 147 147 147 147 147 147 147 147
 ✓ Expr Log Mol ZIC: CTE LA1 RP1 VCA SLIT RP1 SLIT SLIT RP1 SLIT S	Ratio ↑ lecules 3 2 2 2 3 2 2 2 3 2 2 2 3 2 2						+++++++++++++++++++++++++++++++++++++++	Valu 22.9 21.3 20.9 20.3 20.0 19.9 19.1 18.9 18.8 18.5 18.5 18.5 18.5 18.5 18.5 18.5	ie 919 947 925 949 947 924 177 909 989 934 177 909 9389 934 177 909 9389 934 177 909 9389 934 177 909 9389 934 177 909 9389 934 177 909 9389 934 177 909 9389 934 177 909 9389 934 177 909 9389 934 177 909 9389 934 177 909 9389 934 177 909 9389 934 177 909 9389 934 177 909 9389 934 177 909 9389 934 177 177 909 9389 934 177 177 909 9389 934 177 177 199 197 197 197 197 197
 ✓ Expr Log Mol ZIC: CTE LA1 RP1 VCA SLIT RP1 HO2 LOC FEN ✓ Expr Log Mol DD2 UTY TXL RPS PRK USF ACC UTP NLC 	Ratio ↑ lecules 3 0_2636A232 6C_390E65 1_316M112 NN-AS1 TRK3 1_805J145 XD13 C124902301 IDRR Ratio ↓ lecules X3Y NGY 64Y1 29Y 011751.1 214C 5N4Y						++++++++	Valu 22.9 21.3 20.9 20.3 20.0 19.9 19.9 19.9 18.8 18.9 18.9 18.9 18.9	e 919 347 925 349 947 924 177 909 389 534 e 472 289 017 497 364 561 485 476 060

Summary

- independent verification.



autosomal dominant polycystic kidney

normal control renal clear cell carcinoma (KIRC)

Canonical pathways, upstream regulators and causal network in WT 9-7 cells



Figure 4: Comparative expression analysis reveals pathways and regulators in polycystic kidney disease. (A) PCA plot displaying the segregation of normal and kidney cancer samples. (B) Volcano plot showing genes differentially expressed in WT 9-7 cells compared to normal controls. (C) Expression pattern of genes differentially expressed in the WT 9-7 cell line across various renal carcinoma cell lines. (D) Heatmap depicting the activity of indicated pathways in polycystic kidney and normal cells. (E, F) IPA analysis revealing molecular mechanisms in polycystic kidney disease. (G) Differentially expressed genes in the WT 9-7 cell line compared to normal control cell lines.

ATCC[®] Cell Line Land provides a resource of OMICS data for ATCC[®]'s verified and authenticated cell lines that are physically traceable to the repository for cross-validation and

 Utilizing ACLL data enhances reliability, accuracy, and reproducibility in pre-clinical research. ACLL data facilitates suitable model cell line selection for research purposes.

Additionally, ACLL data expedite exploratory research and target identification.

These data can be combined with publicly available data for sanity checks and to ensure scientific rigor and accuracy. ACLL is accessible through QIAGEN® Digital Insights upon subscription. https://digitalinsights.qiagen.com/atcc-cell-line-land/

